Will UnitedHealth Stock Recover?
Shares of embattled health insurance giant UnitedHealth (NYSE:UNH) plummeted by…
Sell
39
BSEM Quote, Financials, Valuation and Earnings
Last price:
$5.8000
Seasonality move
:
160.26%
Day range:
$5.5700 - $5.8900
52-week range:
$3.0932 - $15.7400
Dividend yield:
0%
P/E ratio:
6.81x
P/S ratio:
0.55x
P/B ratio:
1.94x
Volume:
29.1K
Avg. volume:
165.2K
1-year change:
-62.26%
Market cap:
$97.2M
Revenue:
$301.8M
EPS (TTM):
$0.85
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, BioStem Technologies, Inc. has 339.66% upside to fair value with a price target of $25.5000 per share.
BSEM vs. S&P 500
-
Over the past 5 trading days, BioStem Technologies, Inc. has underperformed the S&P 500 by -5.7% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
BioStem Technologies, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
BioStem Technologies, Inc. revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter BioStem Technologies, Inc. reported revenues of $10.5M.
Earnings Growth
-
BioStem Technologies, Inc. earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter BioStem Technologies, Inc. reported earnings per share of $0.03.
Enterprise value:
73.5M
EV / Invested capital:
--
Price / LTM sales:
0.55x
EV / EBIT:
4.80x
EV / Revenue:
0.31x
PEG ratio (5yr expected):
0.17x
EV / Free cash flow:
6.01x
Price / Operating cash flow:
10.55x
Enterprise value / EBITDA:
4.69x
Gross Profit (TTM):
$228.7M
Return On Assets:
17.75%
Net Income Margin (TTM):
8.59%
Return On Equity:
48.25%
Return On Invested Capital:
44.01%
Operating Margin:
13.83%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $5.9M | $146.3M | $235.2M | $18.4M | $10.5M | |
| Gross Profit | $4.9M | $135.2M | $228.7M | $14.1M | $9.2M | |
| Operating Income | -$10.9M | $19.9M | $15.3M | $9.3M | $1.4M | |
| EBITDA | -$10.7M | $20.1M | $15.7M | $9.4M | $1.6M | |
| Diluted EPS | -$0.92 | $0.61 | $0.85 | $0.32 | $0.03 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.1M | $1.9M | $3.8M | $101.4M | $52.7M | |
| Total Assets | $2.9M | $3.9M | $5.8M | $104.2M | $62.4M | |
| Current Liabilities | $6.9M | $5.5M | $7.9M | $81M | $12.2M | |
| Total Liabilities | $8.5M | $6.9M | $9.3M | $81.4M | $12.4M | |
| Total Equity | -$5.6M | -$3M | -$3.5M | $22.8M | $50M | |
| Total Debt | $5.3M | $5M | $5.6M | $4.4M | $3.2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$2.5M | $14.9M | $15.3M | $9.4M | -$2.4M | |
| Cash From Investing | -$280.7K | -$1.5M | -$1.8M | -$1.4M | -$1.2M | |
| Cash From Financing | $1.9M | $1.2M | -$931.9K | -$4.9K | -$135K | |
| Free Cash Flow | -$2.8M | $14.6M | $12.2M | $9.3M | -$4.8M | |
BSEM
Sector
Market Cap
$97.2M
$24M
Price % of 52-Week High
36.85%
48.22%
Dividend Yield
0%
0%
Shareholder Yield
-0.12%
-1.63%
1-Year Price Total Return
-62.26%
-22.68%
Beta (5-Year)
-0.090
0.504
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$6.0943
200-day SMA
Sell
Level
$7.7302
Bollinger Bands (100)
Buy
Level
0 - 0
Chaikin Money Flow
Sell
Level
--
20-day SMA
Sell
Level
$6.0716
Relative Strength Index (RSI14)
Buy
Level
50.4999
ADX Line
Neutral
Level
0
Williams %R
Neutral
Level
-77.6119
50-day SMA
Buy
Level
$4.9788
MACD (12, 26)
Buy
Level
0.2674
25-day Aroon Oscillator
Buy
Level
24
On Balance Volume
Neutral
Level
--
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (4.4251)
Buy
CA Score
(Annual)
Level (1.7525)
Sell
Beneish M-Score
(Annual)
Level (12.6442)
Sell
Momentum Score
Level (1)
Buy
Ohlson Score
Level (0.2257)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (9)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
BioStem Technologies, Inc. engages in the provision of regenerative medicine and anti-aging solutions. It offers pre-treatment assessment, cell therapies, anti-aging, and wellness compounds. The company was founded by Andrew Smith Van Vurst, Henry W. Van Vurst IV, and Jason Matuszewski on April 29, 1939 and is headquartered in Pompano Beach, FL.
Stock Forecast FAQ
In the current month, BSEM has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The BSEM average analyst price target in the past 3 months is $25.5000.
-
Where Will BioStem Technologies, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that BioStem Technologies, Inc. share price will rise to $25.5000 per share over the next 12 months.
-
What Do Analysts Say About BioStem Technologies, Inc.?
Analysts are divided on their view about BioStem Technologies, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that BioStem Technologies, Inc. is a Sell and believe this share price will drop from its current level to $25.5000.
-
What Is BioStem Technologies, Inc.'s Price Target?
The price target for BioStem Technologies, Inc. over the next 1-year time period is forecast to be $25.5000 according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is BSEM A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for BioStem Technologies, Inc. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of BSEM?
You can purchase shares of BioStem Technologies, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase BioStem Technologies, Inc. shares.
-
What Is The BioStem Technologies, Inc. Share Price Today?
BioStem Technologies, Inc. was last trading at $5.8000 per share. This represents the most recent stock quote for BioStem Technologies, Inc.. Yesterday, BioStem Technologies, Inc. closed at $5.8000 per share.
-
How To Buy BioStem Technologies, Inc. Stock Online?
In order to purchase BioStem Technologies, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get BSEM Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
BSEM
Sector
P/E ratio
6.81x
23.16x
PEG ratio
0.17x
-0.01x
P/B ratio
1.94x
1.73x
Price / LTM sales
0.55x
1.50x
Growth Metrics
BSEM
Sector
Revenue growth
-87.31%
3.24%
Earnings growth
-90.71%
11.06%
Revenue (5-year growth)
158.2%
6.28%
Earnings forecast
$0.02
-$0.19
Profitability
BSEM
Sector
Profitability FY 2024
$287.9M
$2.7M
Return on invested capital
44.01%
-33.62%
Return on assets
17.75%
-29.68%
Return on equity
48.25%
-39.33%
Earnings Date
Last Earnings Date
Nov
13
Next Earnings Date
Mar
31
Estimated Next Earnings Date
Feb
12
Balance Sheet
BSEM
Sector
Total cash
$27.2M
$25.1M
Short term investments
--
$23.9M
Total assets
$140.6M
$72.8M
Long term debt
$3.2M
$2.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Lumentum The Best Laser Stock to Buy?
Though certainly less well-known than the huge tech businesses that…
Is Planet Fitness Stock Undervalued?
Planet Fitness (NYSE:PLNT) has had a difficult 12 months, retreating…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 64x
Sell
43
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
42
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 29x
Alerts
Sell
17
ICLR alert for Feb 13
ICON plc [ICLR] is up 15.9% over the past day.
Buy
72
CGNX alert for Feb 14
Cognex Corp. [CGNX] is up 0.31% over the past day.
Buy
77
IPGP alert for Feb 13
IPG Photonics Corp. [IPGP] is up 2.47% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
